StockNews.com began coverage on shares of Cellectis (NASDAQ:CLLS - Free Report) in a research report released on Tuesday. The brokerage issued a sell rating on the biotechnology company's stock.
Cellectis Price Performance
Shares of NASDAQ CLLS traded up $0.04 during mid-day trading on Tuesday, reaching $1.80. 185,677 shares of the company were exchanged, compared to its average volume of 48,472. The stock has a market capitalization of $100.05 million, a PE ratio of -1.38 and a beta of 3.10. The company has a quick ratio of 1.92, a current ratio of 1.92 and a debt-to-equity ratio of 0.39. Cellectis has a 52 week low of $1.75 and a 52 week high of $3.77. The company's 50 day moving average price is $2.09 and its 200 day moving average price is $2.28.
Cellectis (NASDAQ:CLLS - Get Free Report) last issued its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.03). The firm had revenue of $18.05 million during the quarter, compared to analysts' expectations of $5.00 million. Cellectis had a negative return on equity of 78.90% and a negative net margin of 401.83%. During the same period in the prior year, the company earned ($0.31) EPS. Sell-side analysts forecast that Cellectis will post -0.54 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Cellectis
Several institutional investors and hedge funds have recently bought and sold shares of CLLS. XTX Topco Ltd purchased a new stake in Cellectis in the second quarter worth $29,000. First Affirmative Financial Network bought a new stake in shares of Cellectis during the 3rd quarter valued at $45,000. Principal Financial Group Inc. increased its position in Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company's stock valued at $817,000 after buying an additional 12,467 shares in the last quarter. Finally, Long Focus Capital Management LLC raised its holdings in Cellectis by 2.9% in the second quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company's stock worth $8,634,000 after buying an additional 130,000 shares during the last quarter. Hedge funds and other institutional investors own 63.90% of the company's stock.
About Cellectis
(
Get Free Report)
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Featured Articles
Before you consider Cellectis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellectis wasn't on the list.
While Cellectis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
